Welcome

The Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiologists (CAIC) 2018 Focused Update of the Guidelines for the use of Antiplatelet Therapy is highlighted in these 3 slide sets. Using a case-based approach, each set contemplates observational and randomized clinical trial data, together with guideline recommendations, the approach to the use of dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA; Aspirin®) and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor). Specifically, in patients with ST-segment elevation myocardial infarction (STEMI)—either undergoing primary percutaneous coronary intervention (PCI) or receiving fibrinolytic therapy, high risk non-ST-segment elevation myocardial infarction (NSTEMI), and now 1 year post-ACS, clinical issues around the decision-making process of DAPT are raised and addressed.

Dr. Shaun Goodman, the Associate Head of the Division of Cardiology, St. Michael’s Hospital, Professor of Medicine and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto, reviews the key messages from the slide decks in summary recordings, and outlines the important details of each slide within the 3 sets below.

 

Management of a Non-STEMI PCI Patient
VIDEO
SLIDE DECK
SPEAKER NOTES
Management of a STEMI
Patient
VIDEO
SLIDE DECK
SPEAKER NOTES
Management of 1 Year post ACS Patient
VIDEO
SLIDE DECK
SPEAKER NOTES